ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2492

Protective and Pathogenic Effects of the IL-23 Family of Cytokines in Spondyloarthropathy in SKG Mice

Helen Benham1, Linda Rehaume1, Merja Ruutu1, Jared Velasco1, Kristine Kikly2, Geoffrey Strutton3, Michael McGuckin4 and Ranjeny Thomas1, 1Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, 2Biotechnology Discovery Research, Eli Lilly and Co., Indianapolis, 3Dept of Pathology, Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia, 4Mater Medical Research Institute, Brisbane, Australia

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: , IL-23 is required for the expansion and maintenance of T cells and innate cells secreting IL-17 and IL-22. These cytokines are important for control of fungal infections. Genetic studies implicate IL-23 receptor signalling in the pathogenesis of spondyloarthropathies. Spondyloarthritis and Crohn’s-like ileitis develop in an IL-23-dependent fashion in ZAP70-mutant SKG mice, which have deficient T cell receptor signalling. Our aim was to determine the role of IL-23, IL-17 and IL-22 in pathogenesis of spondyloarthritis and ileitis in this model.

Methods: , SKG mice or IL-17A deficient SKG mice were injected intraperitoneally with curdlan (1,3-D β-glucan) to induce disease. Anti-mouse IL-22, anti-IL-23 or isotype control antibodies were given i.p one day before curdlan, and weekly until sacrifice and anti-mouse IL-23 and IL-17A or isotype control antibodies were given in weekly doses commencing three weeks after i.p curdlan in a treatment regime. Outcomes were measured by clinical and histological scoring. Cytokines were measured by quantitative RT-PCR and in supernatants of cultured tissue explants.

Results: Curdlan induced spondyloarthritis in 100% and ileitis in 60% of SKG mice. Weekly anti-IL-23 treatment of SKG mice from induction suppressed development of spondyloarthritis and decreased the severity of ileitis. In curdlan-treated IL-17A deficient SKG mice, or SKG mice treated with anti-IL-17 from induction, spondyloarthritis and ileitis were less severe than control treated mice. In absence of IL-17A, peripheral enthesitis was particularly spared. Treatment with anti-IL-23 or anti-IL-17 three weeks after induction improved spondyloarthritis and ileitis, and anti-IL-23 was significantly more beneficial than anti-IL17. In contrast, anti-IL-22 modestly suppressed arthritis, increased anti-proteoglycan auto antibodies, and exacerbated ileitis. IL-23 mRNA and protein were expressed within days of induction, and increased over time in the ileum, but not in serum, lymph nodes or joint.

Conclusion: In curdlan-treated SKG mice, initiation and perpetuation of spondyloarthritis is dependent on IL-23, likely derived from the gut. IL-17A is particularly associated with enthesitis. Ileal inflammation is dependent on IL-23 and IL-17A and protected by IL-22. The data suggest that beta-glucan promotes IL-23 secretion, with protective and pathogenic consequences in different tissues through T cell cytokines downstream.  Defective T cell signalling in SKG mice not only hinders negative selection of self-reactive T cells but also microbial defence, potentially enhancing the requirement for innate immune mechanisms, including IL-23,  IL-17 and IL-22 for host protection.

 


Disclosure:

H. Benham,
None;

L. Rehaume,
None;

M. Ruutu,
None;

J. Velasco,
None;

K. Kikly,
None;

G. Strutton,
None;

M. McGuckin,
None;

R. Thomas,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/protective-and-pathogenic-effects-of-the-il-23-family-of-cytokines-in-spondyloarthropathy-in-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology